Ulrike Protzer

List of Publications by Year
in descending order

221	14,051	19636	25770
papers	citations	61 h-index	108 g-index

247	247	247	17410
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science, 2014, 343, 1221-1228.	6.0	774
2	Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes. Cancer Cell, 2014, 26, 549-564.	7.7	531
3	Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature, 2021, 594, 246-252.	13.7	475
4	Living in the liver: hepatic infections. Nature Reviews Immunology, 2012, 12, 201-213.	10.6	451
5	Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. Lancet Infectious Diseases, The, 2020, 20, 920-928.	4.6	383
6	Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. Journal of Hepatology, 2011, 55, 996-1003.	1.8	361
7	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	3.7	342
8	Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology, 2009, 50, 1773-1782.	3.6	309
9	Immunosurveillance of the Liver by Intravascular Effector CD8 + T Cells. Cell, 2015, 161, 486-500.	13.5	271
10	Viral hepatitis and liver cancer. Philosophical Transactions of the Royal Society B: Biological Sciences, 2017, 372, 20160274.	1.8	265
11	Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology, 1998, 27, 254-263.	3.6	250
12	Interferon-Î³ and Tumor Necrosis Factor-Î± Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. Gastroenterology, 2016, 150, 194-205.	0.6	250
13	Functional classification of memory CD8+ T cells by CX3CR1 expression. Nature Communications, 2015, 6, 8306.	5.8	231
14	Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nature Medicine, 2022, 28, 496-503.	15.2	215
15	Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection. Nature Immunology, 2013, 14, 574-583.	7.0	196
16	Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology, 2009, 126, 280-289.	2.0	189
17	T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis BÂVirus Envelope Proteins Control Virus Replication in Mice. Gastroenterology, 2013, 145, 456-465.	0.6	180
18	Control of hepatitis B virus at the level of transcription. Journal of Viral Hepatitis, 2010, 17, 527-536.	1.0	172

#	Article	IF	Citations
19	HLA-DRB1*1301 AND *1302 protect against chronic hepatitis B. Journal of Hepatology, 1997, 26, 503-507.	1.8	154
20	Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology, 2012, 55, 287-297.	3.6	147
21	Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. Journal of Hepatology, 2018, 69, 1231-1241.	1.8	147
22	Attacking hepatitis B virus cccDNA â€“ The holy grail to hepatitis B cure. Journal of Hepatology, 2016, 64, S41-S48.	1.8	146
23	Antiviral Activity and Hepatoprotection by Heme Oxygenase-1 in Hepatitis B Virus Infection. Gastroenterology, 2007, 133, 1156-1165.	0.6	143
24	Transfer of Hepatitis B Virus Genome by Adenovirus Vectors into Cultured Cells and Mice: Crossing the Species Barrier. Journal of Virology, 2001, 75, 5108-5118.	1.5	142
25	Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology, 2013, 57, 2358-2368.	3.6	141
26	Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS. Cancer Cell, 2017, 31, 771-789.e6.	7.7	140
27	Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology, 2019, 156, 325-337.	0.6	140
28	T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes. Gastroenterology, 2008, 134, 239-247.	0.6	137
29	Lack of immunological DNA sensing in hepatocytes facilitates hepatitis B virus infection. Hepatology, 2016, 64, 746-759.	3.6	137
30	Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells. PLoS ONE, 2011, 6, e26315.	1.1	132
31	Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain. Journal of Virology, 2012, 86, 10112-10122.	1.5	130
32	The direct and indirect roles of <scp>HBV</scp> in liver cancer: prospective markers for <scp>HCC</scp> screening and potential therapeutic targets. Journal of Pathology, 2015, 235, 355-367.	2.1	116
33	Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology, 1993, 104, 903-905.	0.6	114
34	Heterologous primeâ€“boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infectious Diseases, The, 2021, 21, 1212-1213.	4.6	111
35	Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10818-10823.	3.3	109
36	Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology, 2012, 56, 873-883.	3.6	109

#	Article	IF	Citations
37	Primary human hepatocytes â€“ a valuable tool for investigation of apoptosis and hepatitis B virus infection. Journal of Hepatology, 2003, 38, 736-744.	1.8	105
38	Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. Journal of Hepatology, 2017, 66, 494-503.	1.8	105
39	Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology, 2006, 43, 539-547.	3.6	101
40	PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology, 2017, 66, 398-415.	3.6	101
41	Hepatic Bax Inhibitor-1 Inhibits IRE1Î± and Protects from Obesity-associated Insulin Resistance and Glucose Intolerance. Journal of Biological Chemistry, 2010, 285, 6198-6207.	1.6	98
42	The Global Hepatitis B Virus Genotype Distribution Approximated from Available Genotyping Data. Genes, 2018, 9, 495.	1.0	98
43	Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Research, 2013, 97, 195-197.	1.9	97
44	T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells InÂVitro and inÂMice. Gastroenterology, 2015, 149, 1042-1052.	0.6	96
45	Methyltransferase PRMT1 Is a Binding Partner of HBx and a Negative Regulator of Hepatitis B Virus Transcription. Journal of Virology, 2013, 87, 4360-4371.	1.5	93
46	Revisiting Hepatitis B Virus: Challenges of Curative Therapies. Journal of Virology, 2019, 93, .	1.5	92
47	Inhibition of Cellular Proteasome Activities Enhances Hepadnavirus Replication in an HBX-Dependent Manner. Journal of Virology, 2004, 78, 4566-4572.	1.5	90
48	Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10. Clinical and Experimental Immunology, 1997, 107, 555-561.	1.1	85
49	Control of Hepatitis B Virus by Cytokines. Viruses, 2017, 9, 18.	1.5	82
50	A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine, 2013, 31, 1197-1203.	1.7	78
51	Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice. Gastroenterology, 2020, 158, 1762-1775.e9.	0.6	78
52	Interleukin-10 expression is autoregulated at the transcriptional level in human and murine kupffer cells. Hepatology, 1998, 27, 93-99.	3.6	77
53	A New Class of Synthetic Peptide Inhibitors Blocks Attachment and Entry of Human Pathogenic Viruses. Journal of Infectious Diseases, 2012, 205, 1654-1664.	1.9	75
54	HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans. Science Translational Medicine, 2014, 6, 242ra81.	5.8	74

#	Article	IF	Citations
55	Transfer of HBV Genomes Using Low Doses of Adenovirus Vectors Leads to Persistent Infection in Immune Competent Mice. Gastroenterology, 2012, 142, 1447-1450.e3.	0.6	73
56	A concerted action of HNF4Î± and HNF1Î± links hepatitis B virus replication to hepatocyte differentiation. Cellular Microbiology, 2008, 10, 1478-1490.	1.1	67
57	Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut, 2016, 65, 512-523.	6.1	67
58	5â€² Triphosphorylated Small Interfering RNAs Control Replication of Hepatitis B Virus and Induce an Interferon Response in Human Liver Cells and Mice. Gastroenterology, 2011, 141, 696-706.e3.	0.6	66
59	Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. Medical Microbiology and Immunology, 2021, 210, 65-72.	2.6	66
60	Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus (HBV) Infection: The German Guidelines for the Management of HBV Infection. Zeitschrift Fur Gastroenterologie, 2007, 45, 1281-1328.	0.2	63
61	Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. Journal of Hepatology, 2015, 62, 863-870.	1.8	63
62	Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Current Opinion in Virology, 2018, 30, 58-67.	2.6	62
63	Overnight Resting of PBMC Changes Functional Signatures of Antigen Specific T- Cell Responses: Impact for Immune Monitoring within Clinical Trials. PLoS ONE, 2013, 8, e76215.	1.1	61
64	TNF-Induced Target Cell Killing by CTL Activated through Cross-Presentation. Cell Reports, 2012, 2, 478-487.	2.9	60
65	Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020. Eurosurveillance, 2020, 25, .	3.9	60
66	Therapeutic vaccination for chronic hepatitis B. Current Opinion in Virology, 2017, 23, 75-81.	2.6	59
67	Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques. Nature Communications, 2017, 8, 2146.	5.8	59
68	Apoptosis of Hepatitis B Virus-Infected Hepatocytes Prevents Release of Infectious Virus. Journal of Virology, 2010, 84, 11994-12001.	1.5	56
69	One-Vector System for Multiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNA Utilizing High-Capacity Adenoviral Vectors. Molecular Therapy - Nucleic Acids, 2018, 12, 242-253.	2.3	55
70	Immune Control of Hepatitis B Virus. Digestive Diseases, 2011, 29, 423-433.	0.8	51
71	T cell receptor grafting allows virological control of hepatitis B virus infection. Journal of Clinical Investigation, 2019, 129, 2932-2945.	3.9	51
72	Induction of Antiviral Cytidine Deaminases Does Not Explain the Inhibition of Hepatitis B Virus Replication by Interferons. Journal of Virology, 2007, 81, 10588-10596.	1.5	49

#	Article	IF	Citations
73	Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice. Vaccine, 2016, 34, 923-932.	1.7	48
74	Modified Vaccinia Virus Ankara-Infected Dendritic Cells Present CD4 ⁺ T-Cell Epitopes by Endogenous Major Histocompatibility Complex Class II Presentation Pathways. Journal of Virology, 2015, 89, 2698-2709.	1.5	47
75	Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern. Medical Microbiology and Immunology, 2021, 210, 263-275.	2.6	47
76	Direct Effects of Hepatitis B Virus-Encoded Proteins and Chronic Infection in Liver Cancer Development. Digestive Diseases, 2013, 31, 138-151.	0.8	45
77	Single cell polarity in liquid phase facilitates tumour metastasis. Nature Communications, 2018, 9, 887.	5.8	45
78	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nature Communications, 2022, 13, 153.	5.8	45
79	New pharmacological strategies to fight enveloped viruses. Trends in Pharmacological Sciences, 2014, 35, 470-478.	4.0	42
80	Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model. Molecular Therapy, 2019, 27, 947-959.	3.7	41
81	Bioluminescence imaging allows measuring CD8 T cell function in the liver. Hepatology, 2010, 51, 1430-1437.	3.6	38
82	Interferonâ€induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Reports, 2021, 22, e49568.	2.0	38
83	Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B. Journal of Viral Hepatitis, 2011, 18, 216-226.	1.0	37
84	Liver-specific expression of interferon Î³ following adenoviral gene transfer controls hepatitis B virus replication in mice. Gene Therapy, 2005, 12, 668-677.	2.3	36
85	Molecular detection of hepatitis E virus (HEV) in liver biopsies after liver transplantation. Modern Pathology, 2015, 28, 523-532.	2.9	36
86	Characterization of Pattern Recognition Receptor Expression and Functionality in Liver Primary Cells and Derived Cell Lines. Journal of Innate Immunity, 2018, 10, 339-348.	1.8	36
87	Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment. BMC Microbiology, 2012, 12, 307.	1.3	34
88	Serious outbreak of human metapneumovirus in patients with hematologic malignancies. Leukemia and Lymphoma, 2016, 57, 623-627.	0.6	34
89	N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection. PLoS ONE, 2017, 12, e0170419.	1.1	34
90	A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis. Hepatology, 1997, 26, 478-484.	3.6	32

#	Article	IF	Citations
91	Analyses of HBV cccDNA Quantification and Modification. Methods in Molecular Biology, 2017, 1540, 59-72.	0.4	32
92	A New Role for Capsid Assembly Modulators To Target Mature Hepatitis B Virus Capsids and Prevent Virus Infection. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	32
93	Mucosal-Associated Invariant T (MAIT) Cells Are Highly Activated and Functionally Impaired in COVID-19 Patients. Viruses, 2021, 13, 241.	1.5	31
94	Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter. Journal of Hepatology, 2021, 75, 64-73.	1.8	31
95	Liver Sinusoidal Endothelial Cells Are Not Permissive for Adenovirus Type 5. Human Gene Therapy, 2000, 11, 481-486.	1.4	30
96	Immune Reconstitution After HCV Clearance With Direct Antiviral Agents. Transplantation, 2017, 101, 904-909.	0.5	30
97	Design of therapeutic vaccines: hepatitis B as an example. Microbial Biotechnology, 2012, 5, 270-282.	2.0	29
98	Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology, 2005, 333, 293-300.	1.1	27
99	Response to Comment on â€œSpecific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNAâ€. Science, 2014, 344, 1237-1237.	6.0	27
100	Clinical and Epidemiological Features of a Family Cluster of Symptomatic and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 362-365.	0.6	27
101	Liver-Directed Gamma Interferon Gene Delivery in Chronic Hepatitis C. Journal of Virology, 2005, 79, 13412-13420.	1.5	26
102	The German guideline for the management of hepatitis B virus infection: short version*. Journal of Viral Hepatitis, 2008, 15, 1-21.	1.0	26
103	Norovirus GII.4 and GII.7 capsid sequences undergo positive selection in chronically infected patients. Infection, Genetics and Evolution, 2012, 12, 461-466.	1.0	26
104	Hepatitis B Virus-Infected HepG2^{hNTCP}Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8⁺T CellsIn Vitro. Journal of Virology, 2015, 89, 7433-7438.	1.5	26
105	Endotoxin Stimulates Liver Macrophages To Release Mediators That Inhibit an Early Step in Hepadnavirus Replication. Journal of Virology, 2000, 74, 5525-5533.	1.5	25
106	Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response. Journal of Infectious Diseases, 2016, 214, 1498-1506.	1.9	25
107	IFN-Î±-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection. Scientific Reports, 2017, 7, 12715.	1.6	25
108	Hepatitis B Virus Activates Signal Transducer and Activator of Transcription 3 Supporting Hepatocyte Survival and Virus Replication. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4, 339-363.	2.3	25

#	Article	IF	Citations
109	Applicability of Metal Nanoparticles in the Detection and Monitoring of Hepatitis B Virus Infection. Viruses, 2017, 9, 193.	1.5	25
110	Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection. Scientific Reports, 2019, 9, 10808.	1.6	25
111	Hepatitis B Virus-Based Vectors Allow the Elimination of Viral Gene Expression and the Insertion of Foreign Promoters. Human Gene Therapy, 2004, 15, 203-210.	1.4	24
112	Blocking senseâ€strand activity improves potency, safety and specificity of antiâ€hepatitis B virus short hairpin <scp>RNA</scp>. EMBO Molecular Medicine, 2016, 8, 1082-1098.	3.3	24
113	PASylated interferon Î± efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice. Antiviral Research, 2019, 161, 134-143.	1.9	24
114	Novel viral and host targets to cure hepatitis B. Current Opinion in Virology, 2017, 24, 38-45.	2.6	23
115	Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use. PLoS ONE, 2017, 12, e0182936.	1.1	23
116	Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. Immunology Letters, 2009, 123, 31-37.	1.1	22
117	Novel function of SART1 in HNF4Î± transcriptional regulation contributes to its antiviral role during HBV infection. Journal of Hepatology, 2021, 75, 1072-1082.	1.8	22
118	Long-Term Suppression of Hepatitis B Virus Replication by Short Hairpin RNA Expression Using the Scaffold/Matrix Attachment Region-Based Replicating Vector System pEPI-1. Antimicrobial Agents and Chemotherapy, 2008, 52, 2355-2359.	1.4	21
119	Oncogenic potential of hepatitis B virus encoded proteins. Current Opinion in Virology, 2015, 14, 109-115.	2.6	21
120	Hepatitis B virus replication in primary macaque hepatocytes: Crossing the species barrier toward a new small primate model. Hepatology, 2010, 51, 1954-1960.	3.6	20
121	New norovirus classified as a recombinant GII.g/GII.1 causes an extended foodborne outbreak at a university hospital in Munich. Journal of Clinical Virology, 2013, 58, 24-30.	1.6	20
122	Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro. Journal of Immunology Research, 2017, 2017, 1-12.	0.9	20
123	The hepatitis B epidemic and the urgent need for cure preparedness. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 517-518.	8.2	20
124	Noninvasive chimeric DNA profiling identifies tumor-originated HBV integrants contributing to viral antigen expression in liver cancer. Hepatology International, 2020, 14, 326-337.	1.9	20
125	Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transductionin vitroandin vivo. Hepatology, 2014, 59, 2110-2120.	3.6	19
126	Validation of an IFNÎ³/IL2 FluoroSpot assay for clinical trial monitoring. Journal of Translational Medicine, 2016, 14, 175.	1.8	19

#	Article	IF	Citations
127	â€œTo Be or Not to Beâ€• Immune Tolerance in Chronic Hepatitis B. Gastroenterology, 2016, 151, 805-806.	0.6	19
128	Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virusâ€“Infected Hepatocytes. Journal of Infectious Diseases, 2019, 220, 567-577.	1.9	19
129	Molecular regulation of the hepatic bile acid uptake transporter and HBV entry receptor NTCP. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158960.	1.2	19
130	Recruitment of highly cytotoxic CD8+ TÂcell receptors in mild SARS-CoV-2 infection. Cell Reports, 2022, 38, 110214.	2.9	19
131	Human lysosomal acid lipase inhibitor lalistat impairs Mycobacterium tuberculosis growth by targeting bacterial hydrolases. MedChemComm, 2016, 7, 1797-1801.	3.5	18
132	A dual role for hepatocyte-intrinsic canonical NF-ÎºB signalingÂinÂvirus control. Journal of Hepatology, 2020, 72, 960-975.	1.8	18
133	Self-sampling versus health care professional-guided swab collection for SARS-CoV-2 testing. Infection, 2021, 49, 927-934.	2.3	18
134	A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis. Life Science Alliance, 2019, 2, e201900355.	1.3	18
135	Selection of hepatitis B virus variants with aminoacid substitutions inside the core antigen during interferon-? therapy. Journal of Medical Virology, 2000, 62, 479-486.	2.5	17
136	MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays. Gene Therapy, 2010, 17, 1372-1383.	2.3	17
137	Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp. Vaccine, 2012, 30, 6034-6039.	1.7	17
138	Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin. PLoS ONE, 2014, 9, e96533.	1.1	17
139	Monoclonal antibodies to various epitopes of hepatitis <scp>B</scp> surface antigen inhibit hepatitis <scp>B</scp> virus infection. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1083-1091.	1.4	17
140	Hypoxiaâ€inducible Factor 1 Alphaâ€“Mediated RelB/APOBEC3B Downâ€regulation Allows Hepatitis B Virus Persistence. Hepatology, 2021, 74, 1766-1781.	3.6	17
141	Mouse models for therapeutic vaccination against hepatitis B virus. Medical Microbiology and Immunology, 2015, 204, 95-102.	2.6	16
142	Phantosmia, Parosmia, and Dysgeusia Are Prolonged and Late-Onset Symptoms of COVID-19. Journal of Clinical Medicine, 2021, 10, 5266.	1.0	16
143	Pre-core mutants of hepatitis B virus in patients receiving immunosuppressive treatment after orthotopic liver transplantation. , 1996, 50, 135-144.		15
144	Elevated Epsteinâ€“Barr virus loads and lower antibody titers in competitive athletes. Journal of Medical Virology, 2010, 82, 446-451.	2.5	15

#	Article	IF	Citations
145	Neighbor of punc E11, a novel oncofetal marker for hepatocellular carcinoma. International Journal of Cancer, 2011, 128, 2353-2363.	2.3	15
146	The bumpy road to animal models for HBV infection. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 327-328.	8.2	15
147	Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors. Journal of General Virology, 2016, 97, 121-127.	1.3	15
148	Hepatitis B virus promotes Î²-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion. Oncotarget, 2018, 9, 33947-33960.	0.8	15
149	Innate immune recognition and modulation in hepatitis D virus infection. World Journal of Gastroenterology, 2020, 26, 2781-2791.	1.4	15
150	Depletion of T cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B. Frontiers in Immunology, 2021, 12, 734246.	2.2	15
151	Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. Antiviral Research, 2021, 196, 105197.	1.9	15
152	Herpes simplex virus in bronchoalveolar lavage fluid of medical intensive care unit patients: Association with lung injury and outcome. Journal of Critical Care, 2016, 32, 138-144.	1.0	14
153	Synchronised infection identifies early rateâ€limiting steps in the hepatitis B virus life cycle. Cellular Microbiology, 2020, 22, e13250.	1.1	14
154	Hepatitis B Core Antibody: Role in Clinical Practice in 2020. Current Hepatology Reports, 2020, 19, 254-265.	0.4	14
155	Adoptive Tâ€cell therapy as a therapeutic option for chronic hepatitis B. Journal of Viral Hepatitis, 2007, 14, 45-50.	1.0	13
156	Hepatitis <scp>B</scp> virusâ€specific Tâ€cell responses during <scp>IFN</scp> administration in a small cohort of chronic hepatitis <scp>B</scp> patients under nucleos(t)ide analogue treatment. Journal of Viral Hepatitis, 2014, 21, 633-641.	1.0	13
157	LINE(1)s of Evidence in HBV-Driven Liver Cancer. Cell Host and Microbe, 2014, 15, 249-250.	5.1	13
158	Global Occurrence of Clinically Relevant Hepatitis B Virus Variants as Found by Analysis of Publicly Available Sequencing Data. Viruses, 2020, 12, 1344.	1.5	13
159	Intramolecular recombination enables the formation of hepatitis B virus (HBV) cccDNA in mice after HBV genome transfer using recombinant AAV vectors. Antiviral Research, 2021, 194, 105140.	1.9	13
160	Woodchuck hepatitis virus replication and antigen expression gradually decrease in preneoplastic hepatocellular lineages. Journal of Hepatology, 2002, 37, 478-485.	1.8	12
161	Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models. Scientific Reports, 2020, 10, 14101.	1.6	12
162	Entecavir Allows an Unexpectedly High Residual Replication of HBV Mutants Resistant to Lamivudine. Antiviral Therapy, 2015, 20, 779-787.	0.6	11

#	Article	IF	Citations
163	Schistosome infection aggravates <scp>HCV</scp>â€related liver disease and induces changes in the regulatory Tâ€cell phenotype. Parasite Immunology, 2015, 37, 97-104.	0.7	11
164	A Broad-Spectrum Antiviral Peptide Blocks Infection of Viruses by Binding to Phosphatidylserine in the Viral Envelope. Cells, 2020, 9, 1989.	1.8	11
165	Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes. Journal of Hepatology, 2020, 73, 1347-1359.	1.8	11
166	T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice. Journal of Hepatology, 2021, 75, 1058-1071.	1.8	11
167	Control of APOBEC3B induction and cccDNA decay by NF-ÎºB and miR-138-5p. JHEP Reports, 2021, 3, 100354.	2.6	11
168	Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunity. Nature Communications, 2022, 13, .	5.8	11
169	Epigenetic control of HBV by HBx proteinâ€"releasing the break?. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 558-559.	8.2	10
170	Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg). Antiviral Research, 2017, 144, 153-163.	1.9	10
171	Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an early step in the virus life cycle. Antiviral Research, 2018, 151, 4-7.	1.9	10
172	Towards curative therapy of chronic viral hepatitis. Zeitschrift Fur Gastroenterologie, 2019, 57, 61-73.	0.2	10
173	Dynamic, Helminth-Induced Immune Modulation Influences the Outcome of Acute and Chronic Hepatitis B Virus Infection. Journal of Infectious Diseases, 2020, 221, 1448-1461.	1.9	10
174	A PCR assay to quantify patterns of HBV transcription. Journal of General Virology, 2021, 102, .	1.3	10
175	Rapid and Robust Continuous Purification of High-Titer Hepatitis B Virus for In Vitro and In Vivo Applications. Viruses, 2021, 13, 1503.	1.5	10
176	Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24highCD38high Regulatory B Cells and Lower Levels of IL-10 Expression Compared to Responders. Frontiers in Immunology, 2021, 12, 713351.	2.2	10
177	Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing. Computational and Structural Biotechnology Journal, 2022, 20, 799-811.	1.9	10
178	Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany. Emerging Infectious Diseases, 2022, 28, 572-581.	2.0	10
179	PD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis B. Biomolecules, 2022, 12, 470.	1.8	10
180	Rare pre-core stop-codon mutant nt. 1897 predominates over wide-spread mutant nt. 1896 in an unusual course of chronic hepatitis B. Journal of Viral Hepatitis, 1996, 3, 155-162.	1.0	9

#	Article	IF	Citations
181	Isolated norovirus GII.7 strain within an extended GII.4 outbreak. Journal of Medical Virology, 2010, 82, 1058-1064.	2.5	9
182	Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study. Infectious Agents and Cancer, 2015, 10, 31.	1.2	9
183	Outcome of Antiviral Immunity in the Liver Is Shaped by the Level of Antigen Expressed in Infected Hepatocytes. Hepatology, 2018, 68, 2089-2105.	3.6	9
184	Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design. Nature Communications, 2021, 12, 6737.	5.8	9
185	Antiviral Gene Therapy. Handbook of Experimental Pharmacology, 2009, , 265-297.	0.9	8
186	Nef-specific CD45RA+ CD8+ T cells secreting MIP-1Î² but not IFN-Î³ are associated with nonprogressive HIV-1 infection. AIDS Research and Therapy, 2010, 7, 20.	0.7	8
187	Mitosis of hepatitis B virus-infected cells inÂvitro results in uninfected daughter cells. JHEP Reports, 2022, 4, 100514.	2.6	8
188	Linear B-Cell Epitopes in Human Norovirus GII.4 Capsid Protein Elicit Blockade Antibodies. Vaccines, 2021, 9, 52.	2.1	7
189	Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work!. Journal of Hepatology, 2020, 73, 449-451.	1.8	6
190	Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection. Vaccines, 2021, 9, 841.	2.1	6
191	Efficient and reproducible depletion of hepatitis B virus from plasma derived extracellular vesicles. Journal of Extracellular Vesicles, 2020, 10, e12040.	5.5	6
192	Adoptive T-cell therapy to treat liver cancer: Is the liver microenvironment key?. Oncotarget, 2013, 4, 1117-1118.	0.8	6
193	Intensive Care Risk Estimation in COVID-19 Pneumonia Based on Clinical and Imaging Parameters: Experiences from the Munich Cohort. SSRN Electronic Journal, 0, , .	0.4	6
194	Concentration of Na+-taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus. Scientific Reports, 2021, 11, 19799.	1.6	6
195	Carving the CAR. Gene Therapy, 2010, 17, 1191-1192.	2.3	5
196	Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism. Journal of Molecular Medicine, 2022, 100, 613-627.	1.7	5
197	Construction of Recombinant Adenoviruses that Produce Infectious Hepatitis B Virus. , 2004, 96, 209-218.		4
198	Longitudinal changes in HIV-1-specific T-cell quality associated with viral load dynamic. Journal of Clinical Virology, 2012, 55, 114-120.	1.6	4

#	Article	IF	Citations
199	Characterization of a library of 20 HBV-specific MHC class II-restricted T cell receptors. Molecular Therapy - Methods and Clinical Development, 2021, 23, 476-489.	1.8	4
200	Ethanol attenuates presentation of cytotoxic Tâ€lymphocyte epitopes on hepatocytes of HBVâ€infected humanized mice. Alcoholism: Clinical and Experimental Research, 2022, 46, 40-51.	1.4	4
201	Improving Therapeutic Vaccination against Hepatitis Bâ€"Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection. Vaccines, 2021, 9, 1333.	2.1	4
202	Hepatitis B virus X protein counteracts high mobility group box 1 protein-mediated epigenetic silencing of covalently closed circular DNA. PLoS Pathogens, 2022, 18, e1010576.	2.1	4
203	Presence of Replicating Virus in Recombinant Hepadnavirus Stocks Results from Recombination and Can Be Eliminated by the Use of a Packaging Cell Line. Journal of Virology, 2003, 77, 2873-2881.	1.5	3
204	Overexpression of STAT-1 by adenoviral gene transfer does not inhibit hepatitis B virus replication. European Journal of Gastroenterology and Hepatology, 2006, 18, 167-174.	0.8	3
205	Evaluation of T-activated proteins as recall antigens to monitor Epsteinâ€"Barr virus and human cytomegalovirus-specific T cells in a clinical trial setting. Journal of Translational Medicine, 2020, 18, 242.	1.8	3
206	Increased HERV-K(HML-2) Transcript Levels Correlate with Clinical Parameters of Liver Damage in Hepatitis C Patients. Cells, 2021, 10, 774.	1.8	3
207	Prolonged norovirus infections correlate to quasispecies evolution resulting in structural changes of surface-exposed epitopes. IScience, 2021, 24, 102802.	1.9	3
208	Fetomaternal immune cross talk modifies T-cell priming through sustained changes to DC function. Journal of Allergy and Clinical Immunology, 2021, 148, 843-857.e6.	1.5	3
209	Hepatitis-D Virus Infection Is Not Impaired by Innate Immunity but Increases Cytotoxic T-Cell Activity. Cells, 2021, 10, 3253.	1.8	3
210	Quantitation of norovirus-specific IgG before and after infection in immunocompromised patients. Brazilian Journal of Microbiology, 2020, 51, 183-187.	0.8	2
211	Risk Reduction of Cervical Cancer Through HPV Screening and Vaccinationâ€"Assumptions and Reality. , 2014, , 459-476.		2
212	Identification and Characterization of Antigen-Specific CD8+ T Cells Using Surface-Trapped TNF-Î± and Single-Cell Sequencing. Journal of Immunology, 2021, , ji2100535.	0.4	2
213	Hepatitis B Virus X Protein: A Key Regulator of the Virus Life Cycle. , 2012, , .		1
214	8. Hepatitis viruses. , 2014, , 113-124.		1
215	Visualizing HEV infection in human liver tissue. Journal of Hepatology, 2017, 67, 443-445.	1.8	1
216	Novel rtM204 Mutations in HBV Polymerase Confer Reduced Susceptibility to Adefovir and Tenofovir. Journal of Antivirals & Antiretrovirals, 2017, 09, .	0.1	1

#	Article	IF	Citations
217	Hepatitis B virus envelope proteins can serve as therapeutic targets embedded in the host cell plasma membrane. Cellular Microbiology, 2021, 23, e13399.	1.1	1
218	In Vivo Bioluminescence Imaging of HBV Replicating Hepatocytes Allows for the Monitoring of Anti-Viral Immunity. Viruses, 2021, 13, 2273.	1.5	1
219	A Telemedicine-Guided Self-Collection Approach for PCR-Based SARS-CoV-2 Testing: Comparative Study. JMIR Formative Research, 2022, 6, e32564.	0.7	1
220	Transfer of HBV Genomes into Mice. , 2005, 25, 33-41.		0
221	Innate Immunity and Disorders of the Liver. , 2014, , 65-77.		0